END-AF 1

Clinical randomised Phase II trial of AP31969 versus Placebo for Rhythm control of atrial fibrillation

Stage: inclusie
Medicine: AP31969
Population: Ritme
Phase: II
First Patient In: 24 November 2025
Last Patient In: 31 March 2027
Last Patient Last Visit: 1 July 2027

Inclusion period, 200 days remaining

Study Director

dr. R.G. Tieleman

Cardioloog

Office Contact

M.J. van Doorn

Studiemanager